Mr. Liu is a Cofounder of Health Guard, and was Vice General Manager since the inception of the company before getting promoted to General Manager in 2016. He has been leading the company’s relentless efforts to develop HPV vaccines and other innovative recombinant vaccines over the past decade. Mr. Liu is a recipient of Special Government Allowance sponsored by the State Council and a 2015 Innovation Project-Etown Outstanding Experts. He garnered a National Science & Technology Progress Award (Third Prize).
Mr. Hao has been with Health Guard since 2012, serving as General Manager. From April 2016 to June 2023, he was the Chairman of the Board. In August 2019, Mr. Hao was appointed the CEO of the company until June 2023. Over the years, he has led the restructuring of the company as a shareholding enterprise, the listing of the company on the NEEQ, and the conclusion of Series A/B/C/D funding rounds at premium prices. In March 2023, the company was successfully listed on Beijing Stock Exchange under his leadership.
Mr. Tao majored in urban planning in Heilongjiang City Construction Engineering School. From September 2007 through November 2018, he was the former General Manager of Heilongjiang Sirius Power Plant Equipment Co., Ltd. Mr. Tao has been with Health Guard since October 2008, serving as the board member of the company before and after the restructuring of the company as a shareholding enterprise until November 2021. From January 2017 to June 2023, he was board president of Sirius Holding Group.
Ms. Dong joined the company in 2015, and had served as head of Finance Department and Finance Director before she was promoted to CFO in 2019.
She was an audit manager at Beijing Tianniu Investment from 2012-2015. Prior to that, Ms. Dong served as a finance manager at Heihe Xinghe Electricity.
Ms. Dong was a Certified Public Accountant.
Dr. Zhang joined the company in 2014, and served as head of the Formulation Department prior to being promoted to Vice General Manager (R&D) in 2016.
Previously, Dr. Zhang served as an R&D director at AbMax Biotechnology. He was a research associate at Cancer Institute of Chinese Academy of Medical Sciences from 2011 to 2012, and a research associate at Institute of Zoology of Chinese Academy of Sciences from 2009 to 2011.
Dr. Zhang received his Ph.D. from Beijing Normal University in 2004 and completed his postdoctoral training at Vanderbilt University. He was a 2017 Innovation Project-Etown Outstanding Expert.
Mr. Shen started at the company in 2011 and was promoted to Vice General Manager (Quality) in April 2013. He is the Qualified Person for product quality at the company.
Mr. Shen had previously served in various executive roles across the industry, including as Vice General Manager（Manufacturing）and Vice General Manager (Quality), respectively, at Harbin Laiboten Pharmaceutical, Chief Engineer and Qualified Person at Heilongjiang Fuhe Huxing Pharmaceutical, and Manufacturing and Technical Director at Sunflower Pharmaceutical.
Mr. Shen received a master’s degree in polymer materials from Harbin University of Science and Technology.
Ms. Zhang joined the company in 2011 and have held multiple roles, including QA Supervisor, Pilot Plant Supervisor, Head of Process Development Department and Assistant to the vice General Manager. In July 2020, Ms. Zhang was appointed Vice General Manger of Beijing Health Guard and Health Guard (Kunming) in charge of process development and procurement.
Prior to joining the company, Ms. Zhang had worked for Gooddoctor Pharmaceutical Group and Zhendong Pharmaceutical, respectively, serving a variety of manufacturing, production and quality roles.
Ms. Zhang received a master’s degree in bioengineering from Beijing Institute of Technology.
Mr. Yi Joined BHGB in 2014 and served as the Secretary of the company.
Mr. Yi graduated from China University of Petroleum with a major in Computer Science and Technology. Mr Yi has accumulated over 15 years of experience in business management and strategic development.